Please enable JavaScript to continue using this application.

Compare $ANNX vs $FDMT | Chartloom

Compare

$ANNX vs $FDMT

Annexon Inc · 4D Molecular Therapeutics Inc

ANNX

Annexon Inc

FDMT

4D Molecular Therapeutics Inc

Compare $ANNX vs $FDMT

Comparing Annexon Inc and 4D Molecular Therapeutics Inc

ANNXAnnexon Inc

FDMT4D Molecular Therapeutics Inc

ANNXAnnexon Inc

Market cap

$659M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.66x

Rev growth (TTM)

—

YTD performance

-14.3%

52W performance

27.6%

FCF yield

-29.3%

FDMT4D Molecular Therapeutics Inc

Market cap

$697M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

50.39x

Rev growth (TTM)

278712.1%

YTD performance

82.1%

52W performance

38.0%

FCF yield

-22.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ANNX

FDMT

Detailed metrics comparison

ANNX

Annexon Inc

FDMT

4D Molecular Therapeutics Inc

Market Cap

ANNX$659M

FDMT$697M

Enterprise Value

ANNX$459M

FDMT$646M

Price

ANNX$4.02

FDMT$13.33

P/E Ratio

ANNXN/A

FDMTN/A

P/S Ratio

ANNX0.00x

FDMT7.57x

EV/Sales

ANNX0.00x

FDMT7.02x

EV/EBITDA

ANNX0.00x

FDMT0.00x

P/B Ratio

ANNX4.27x

FDMT1.85x

P/FCF Ratio

ANNXN/A

FDMTN/A

EV/FCF

ANNX-2.38x

FDMT-4.13x

PEG Ratio

ANNXN/A

FDMTN/A

Forward P/E (NTM)

ANNXN/A

FDMTN/A

Forward P/S (NTM)

ANNX21.66x

FDMT50.39x

Revenue (TTM)

ANNX$0

FDMT$92M

Revenue Growth (YoY)

ANNXN/A

FDMT278712.1%

Forward Rev Growth

ANNX370.6%

FDMT40.6%

Gross Margin (TTM)

ANNX0.0%

FDMT0.0%

Operating Margin (TTM)

ANNX0.0%

FDMT0.0%

EBITDA Margin (TTM)

ANNX0.0%

FDMT-208.8%

Net Margin (TTM)

ANNX0.0%

FDMT-194.7%

FCF Margin (TTM)

ANNXN/A

FDMT-169.9%

Net Income (TTM)

ANNX$-203M

FDMT$-179M

FCF (TTM)

ANNX$-193M

FDMT$-156M

EPS (TTM)

ANNX-$1.01

FDMT-$2.55

ROE (TTM)

ANNX-10615.0%

FDMT-4133.0%

ROA (TTM)

ANNX-7982.0%

FDMT-3590.0%

ROIC (TTM)

ANNX-10615.0%

FDMT-4087.0%

Cash

ANNX$199M

FDMT$70M

Debt

ANNX$0

FDMT$20M

Net Cash/Debt

ANNX$199M

FDMT$51M

Current Ratio (TTM)

ANNX5.53x

FDMT8.03x

Quick Ratio (TTM)

ANNX5.44x

FDMT7.68x

Debt/Equity (TTM)

ANNX0.00x

FDMT0.05x

Debt/Assets (TTM)

ANNX0.0%

FDMT0.0%

Interest Coverage (TTM)

ANNXN/A

FDMTN/A

Net Debt/EBITDA (TTM)

ANNX0.00x

FDMT0.00x

Beta

ANNX1.40

FDMT2.90

52W Performance

ANNX27.6%

FDMT38.0%

YTD Performance

ANNX-14.3%

FDMT82.1%

% from 52W High

ANNX-44.0%

FDMT-21.3%

% from 52W Low

ANNX58.3%

FDMT91.5%

Asset Turnover (TTM)

ANNX0.00x

FDMT0.18x

FCF Yield (TTM)

ANNX-29.3%

FDMT-22.4%

Earnings Yield (TTM)

ANNX-30.8%

FDMT-25.7%

Dividend Yield (TTM)

ANNXN/A

FDMTN/A

Rule of 40

ANNX0.0

FDMT278,542.3

EV/GP/RG

ANNXN/A

FDMTN/A

Ticker research

View ANNX research View FDMT research

Metric	ANNX Annexon Inc	FDMT 4D Molecular Therapeutics Inc
Market & Valuation
Market Cap	$659M	$697M
Enterprise Value	$459M	$646M
Price	$4.02	$13.33
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	7.57x
EV/Sales	0.00x	7.02x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.27x	1.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.38x	-4.13x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.66x	50.39x
Revenue & Growth
Revenue (TTM)	$0	$92M
Revenue Growth (YoY)	N/A	278712.1%
Forward Rev Growth	370.6%	40.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-208.8%
Net Margin (TTM)	0.0%	-194.7%
FCF Margin (TTM)	N/A	-169.9%
Net Income (TTM)	$-203M	$-179M
FCF (TTM)	$-193M	$-156M
EPS (TTM)	-$1.01	-$2.55
ROE (TTM)	-10615.0%	-4133.0%
ROA (TTM)	-7982.0%	-3590.0%
ROIC (TTM)	-10615.0%	-4087.0%
Financial Health
Cash	$199M	$70M
Debt	$0	$20M
Net Cash/Debt	$199M	$51M
Current Ratio (TTM)	5.53x	8.03x
Quick Ratio (TTM)	5.44x	7.68x
Debt/Equity (TTM)	0.00x	0.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.40	2.90
52W Performance	27.6%	38.0%
YTD Performance	-14.3%	82.1%
% from 52W High	-44.0%	-21.3%
% from 52W Low	58.3%	91.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.18x
FCF Yield (TTM)	-29.3%	-22.4%
Earnings Yield (TTM)	-30.8%	-25.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	278,542.3
EV/GP/RG	N/A	N/A
Ticker research	View ANNX research	View FDMT research

Valuation

P/S Ratio

ANNX

0.00x

FDMT

7.57x

EV/FCF

FDMT

-4.13x

ANNX

-2.38x

Growth & revenue

Revenue Growth TTM

FDMT

278712.1%

Forward Revenue Growth

ANNX

370.6%

FDMT

40.6%

Profitability & performance

Gross Margin

ANNX

0.0%

FDMT

0.0%

ROE

FDMT

-4133.0%

ANNX

-10615.0%

FCF Yield %

FDMT

-22.4%

ANNX

-29.3%

52-Week Performance

FDMT

38.0%

ANNX

27.6%

Detailed metrics comparison

ANNX

Annexon Inc

FDMT

4D Molecular Therapeutics Inc

Market Cap

ANNX$659M

FDMT$697M

Enterprise Value

ANNX$459M

FDMT$646M

Price

ANNX$4.02

FDMT$13.33

P/E Ratio

ANNXN/A

FDMTN/A

P/S Ratio

ANNX0.00x

FDMT7.57x

EV/Sales

ANNX0.00x

FDMT7.02x

EV/EBITDA

ANNX0.00x

FDMT0.00x

P/B Ratio

ANNX4.27x

FDMT1.85x

P/FCF Ratio

ANNXN/A

FDMTN/A

EV/FCF

ANNX-2.38x

FDMT-4.13x

PEG Ratio

ANNXN/A

FDMTN/A

Forward P/E (NTM)

ANNXN/A

FDMTN/A

Forward P/S (NTM)

ANNX21.66x

FDMT50.39x

Revenue (TTM)

ANNX$0

FDMT$92M

Revenue Growth (YoY)

ANNXN/A

FDMT278712.1%

Forward Rev Growth

ANNX370.6%

FDMT40.6%

Gross Margin (TTM)

ANNX0.0%

FDMT0.0%

Operating Margin (TTM)

ANNX0.0%

FDMT0.0%

EBITDA Margin (TTM)

ANNX0.0%

FDMT-208.8%

Net Margin (TTM)

ANNX0.0%

FDMT-194.7%

FCF Margin (TTM)

ANNXN/A

FDMT-169.9%

Net Income (TTM)

ANNX$-203M

FDMT$-179M

FCF (TTM)

ANNX$-193M

FDMT$-156M

EPS (TTM)

ANNX-$1.01

FDMT-$2.55

ROE (TTM)

ANNX-10615.0%

FDMT-4133.0%

ROA (TTM)

ANNX-7982.0%

FDMT-3590.0%

ROIC (TTM)

ANNX-10615.0%

FDMT-4087.0%

Cash

ANNX$199M

FDMT$70M

Debt

ANNX$0

FDMT$20M

Net Cash/Debt

ANNX$199M

FDMT$51M

Current Ratio (TTM)

ANNX5.53x

FDMT8.03x

Quick Ratio (TTM)

ANNX5.44x

FDMT7.68x

Debt/Equity (TTM)

ANNX0.00x

FDMT0.05x

Debt/Assets (TTM)

ANNX0.0%

FDMT0.0%

Interest Coverage (TTM)

ANNXN/A

FDMTN/A

Net Debt/EBITDA (TTM)

ANNX0.00x

FDMT0.00x

Beta

ANNX1.40

FDMT2.90

52W Performance

ANNX27.6%

FDMT38.0%

YTD Performance

ANNX-14.3%

FDMT82.1%

% from 52W High

ANNX-44.0%

FDMT-21.3%

% from 52W Low

ANNX58.3%

FDMT91.5%

Asset Turnover (TTM)

ANNX0.00x

FDMT0.18x

FCF Yield (TTM)

ANNX-29.3%

FDMT-22.4%

Earnings Yield (TTM)

ANNX-30.8%

FDMT-25.7%

Dividend Yield (TTM)

ANNXN/A

FDMTN/A

Rule of 40

ANNX0.0

FDMT278,542.3

EV/GP/RG

ANNXN/A

FDMTN/A

Ticker research

View ANNX research View FDMT research

Metric	ANNX Annexon Inc	FDMT 4D Molecular Therapeutics Inc
Market & Valuation
Market Cap	$659M	$697M
Enterprise Value	$459M	$646M
Price	$4.02	$13.33
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	7.57x
EV/Sales	0.00x	7.02x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.27x	1.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.38x	-4.13x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.66x	50.39x
Revenue & Growth
Revenue (TTM)	$0	$92M
Revenue Growth (YoY)	N/A	278712.1%
Forward Rev Growth	370.6%	40.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-208.8%
Net Margin (TTM)	0.0%	-194.7%
FCF Margin (TTM)	N/A	-169.9%
Net Income (TTM)	$-203M	$-179M
FCF (TTM)	$-193M	$-156M
EPS (TTM)	-$1.01	-$2.55
ROE (TTM)	-10615.0%	-4133.0%
ROA (TTM)	-7982.0%	-3590.0%
ROIC (TTM)	-10615.0%	-4087.0%
Financial Health
Cash	$199M	$70M
Debt	$0	$20M
Net Cash/Debt	$199M	$51M
Current Ratio (TTM)	5.53x	8.03x
Quick Ratio (TTM)	5.44x	7.68x
Debt/Equity (TTM)	0.00x	0.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.40	2.90
52W Performance	27.6%	38.0%
YTD Performance	-14.3%	82.1%
% from 52W High	-44.0%	-21.3%
% from 52W Low	58.3%	91.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.18x
FCF Yield (TTM)	-29.3%	-22.4%
Earnings Yield (TTM)	-30.8%	-25.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	278,542.3
EV/GP/RG	N/A	N/A
Ticker research	View ANNX research	View FDMT research